Gastrointestinal Cancer

Patients with unresectable hepatocellular carcinoma who received rivoceranib/camrelizumab achieved a median progression-free survival of 5.6 months vs 3.7 months with sorafenib.

Trastuzumab deruxtecan elicited a confirmed objective response rate of 42% in patients with HER2-positive gastric or gastroesophageal junction cancer, according to findings from the phase 2 DESTINY-Gastric02 trial.

By 3 months postsurgery, most older patients with colon or rectal cancer had achieved functional recovery.

The FDA has granted priority review to the biologics license application for zolbetuximab as a treatment for patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

The median overall survival with intra-arterial gemcitabine was 15.7 months vs 10.1 months with intravenous gemcitabine and nab-paclitaxel.

Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.

Mitazalimab and modified FOLFIRINOX produced a 57% objective response rate among patients with metastatic pancreatic ductal adenocarcinoma in the frontline setting.

FOLFOX was associated with lower rates or diarrhea and bowel dysfunction, but higher rates of fatigue, anxiety, nausea, and neuropathy, in data from the phase 2/3 PROSPECT trial.

The FDA has launched a priority review of fruquintinib as treatment for adult patients with previously treated metastatic colorectal cancer.

Adverse experiences, such as smoking and experiencing physical abuse, do not necessarily decrease the frequency of colorectal cancer screenings.

Patients with HER2-positive, metastatic colorectal cancer derived clinical benefit from a 5.4 mg/kg dose of trastuzumab deruxtecan.

In the phase 2 DESTINY-PanTumor02 trial, trastuzumab deruxtecan elicited clinical activity across a range of HER2 expressing solid tumors.

Preoperative FOLFOX demonstrated noninferior efficacy outcomes vs preoperative chemoradiation in locally advanced rectal cancer.

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

Manufacturers believe that GEN-002/avelumab holds promise as a third-line option for patients with gastric cancer and PD-L1 expression.

Patients with pancreatic and gastric cancers residing in states with expanded Medicaid had improved survival rates.

Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.

Treatment with encorafenib in combination with cetuximab and binimetinib was active with a manageable safety profile in the first-line setting for patients with BRAF V600E–mutated metastatic colorectal cancer.

Single-agent adagrasib demonstrated a manageable safety profile and meaningful clinical activity in patients with KRAS G12C–mutated solid tumors.

Kathleen Gander DNP, APRN, CNS; and Sarah Middlekauff, MSN, RN, OCN, relay their experiences in implementing a hepatic artery infusion pump educational intervention for oncology nurses.

An estimated 54.5% of adolescents in the United States have received the recommended doses of the HPV vaccine, although the government established a goal of an 80% vaccination rate in this population.

Trifluridine plus tipiracil, with or without bevacizumab, has been granted priority review status for the treatment of refractory, metastatic colorectal cancer.

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.

Combined adjuvant treatment with atezolizumab and bevacizumab was determined to deliver a statistically significant recurrence-free survival benefit to patients with resected hepatocellular carcinoma.

Investigators continue to explore new ways to manage colorectal cancer with a BRAF V600E mutation.